UnitedHealth Group reported strong Q1 results with a 15% increase in revenue and a 14% rise in adjusted EPS, exceeding expectations. The company also raised its full-year adjusted EPS outlook to $24.50-$25, reflecting confidence in ongoing growth across its businesses. This positive performance and optimistic guidance are likely to positively impact the stock price in the short term.

[1]